Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 215

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Effect of Valsartan on Systemic Right Ventricular Function: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial

van der Bom, Teun, Winter, Michiel M., Bouma, Berto J., Groenink, Maarten, Vliegen, Hubert W., Pieper, Petronella G., van Dijk, Arie P.J., Sieswerda, Gertjan T., Roos-Hesselink, Jolien W., Zwinderman, Aeilko H., Mulder, Barbara J.M. · 2013 · Circulation

Abstract

Background—: The role of angiotensin II receptor blockers in patients with a systemic right ventricle has not been elucidated. Methods and Results—: We conducted a multicenter, double-blind, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice daily compared with placebo in patients with a systemic right ventricle caused by congenitally or surgically corrected transposition of the great arteries. The primary end point was change in right ventricular ejection fraction during 3-year follow-up, determined by cardiovascular magnetic resonance imaging or, in patients with contraindication for magnetic resonance imaging, multirow detector computed tomography. Secondary end points were change in right ventricular volumes and mass, peak, and quality of life. Primary analyses were performed on an intention-to-treat basis. A total of 88 patients (valsartan, n=44; placebo, n=44) were enrolled in the trial. No serious adverse effects occurred in either group. There was no significant effect of 3-year valsartan therapy on systemic right ventricular ejection fraction (treatment effect, 1.3%; 95% confidence interval, −1.3% to 3.9%; P =0.34), maximum exercise capacity, or quality of life. There was a larger increase in right ventricular end-diastolic volume (15 mL; 95% confidence interval, 3–28 mL; P <0.01) and mass (8 g; 95% confidence interval, 2–14 g; P =0.01) in the placebo group than in the valsartan group. Conclusions—: There was no significant treatment effect of valsartan on right ventricular ejection fraction, exercise capacity, or quality of life. Valsartan was associated with a similar frequency of significant clinical events as placebo. Small but significant differences between valsartan and placebo were present for change in right ventricular volumes and mass. Clinical Trial Registration—: URL: http://www.controlled-trials.com . Unique identifier: ISRCTN52352170.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.112.135392

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 215

Metadata

Authors
van der Bom, T., Winter, M. M., Bouma, B. J., Groenink, M., Vliegen, H. W., Pieper, P. G., van Dijk, A. P. J., Sieswerda, G. T., Roos-Hesselink, J. W., Zwinderman, A. H., & Mulder, B. J. M.
Venue
Circulation
Published
2013-01-22
Volume
127
Issue
3
Pages
322-330
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2125921590
Cited by
215
References
4
FWCI
9.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Valsartan on Systemic Right Ventricular Function: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial. https://app.cochat.ai/papers/10.1161/circulationaha.112.135392
The paper
van der Bom, T., Winter, M. M., Bouma, B. J., Groenink, M., Vliegen, H. W., Pieper, P. G., van Dijk, A. P. J., Sieswerda, G. T., Roos-Hesselink, J. W., Zwinderman, A. H., & Mulder, B. J. M. (2013). Effect of Valsartan on Systemic Right Ventricular Function: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial. Circulation. https://doi.org/10.1161/circulationaha.112.135392

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.